


# UROVALVE

Company Fact Sheet

FREEDOM • FUNCTION • CONTROL

**Urovalve is a medical device company focused on creating products for urinary flow and control.** The Company's initial product in development, the **Surinate® Bladder Management System**, is designed to significantly improve the plight of men who suffer from **acute and chronic urinary retention** (inability to empty the bladder) caused by obstruction of the urethra. It is a common and distressing problem that may have a profound impact on quality of life. Men currently have to rely either on a half-century-old product called the Foley catheter, or intermittent catheterization four to six times *a day*. Both kinds of devices cause tremendous patient sacrifices in terms of *freedom, function and control*.

**The Surinate® Bladder Management System is designed to restore *freedom, function and control*—“freedom”, because the patient is no longer tied to an external bag; there are no external tubes required for Surinate®; “function”, because Surinate® has a unique and proprietary magnetized valve that allows the bladder to fill and then empty only on command of the patient, so the *normal* filling and emptying cycle of the bladder is restored; and, “control”, because the patient uses an external magnet to open the valve in the Surinate® catheter to drain the bladder *when he needs to*. The patient thus has self-control over the bladder-emptying process.**



© 2008 Golgeon Group, Inc.

**The potential market for Surinate® is extraordinary.** There are over 92 million urinary catheters sold in the United States each year, and the global market is estimated at \$3 billion. Even a modest share of the urinary catheter market in various segments projects to potential Urovalve sales in excess of \$250 million within five years of a Surinate® launch—because the Surinate® system is designed to free users from reliance on conventional catheters that limit activities, damage self-image, and cause a high incidence of serious urinary tract infections (UTIs). No other devices combine the utility, ease of use, and cost benefits of Surinate®.

**Urinary tract infections (UTIs) are a major problem with currently available urinary catheters.** Sixty-five percent of intermittent catheter users get a UTI at least once per year. Some 840,000 UTIs are caused annually by catheters in patients being treated in acute care facilities. **These are nosocomial infections related to urinary catheter use and a healthcare burden of about \$3.5 billion a year that CMS (Centers for Medicare and Medicaid Services) has recently said it will no longer pay for...** a very important hospital cost and, more importantly, a very important risk to patients. Because nothing in Surinate® extends to the outside of the body, patients have freedom from external tubes or bags and there is no route for bacterial migration that exists with the current technology, either with the Foley catheter in place or with the insertion of an intermittent catheter four to six times a day.

## Key Information

### Headquarters

Urovalve, Inc.  
211 Warren Street  
Newark, NJ 07103  
(973) 596-1350

**Website** www.urovalve.com

**Financing** Privately held

**Sector** Medical devices

**Employees** 5

**Contact:** Ronald Trahan, APR, Pres.  
Ronald Trahan Asso. Inc.  
(508) 359-4005, x108

## Management, Advisers

**Harvey D. Homan, PhD, MBA**  
President and Chief Executive Officer

**Thomas W. Winegar, BSME, MBA**  
Chief Technology Officer

**Subbarao V. Yalla, MD**  
Chief Medical Adviser

**David L. West, PhD, MPH**  
Chief Regulatory Affairs Adviser

## Scientific Advisory Board

**Vincent De Caprio, PhD**  
Trustee, NJ Institute of Technology

**Joseph Di Trolio, MD**  
Clin. Prof. of Surgery, NJ Sch. of Medicine

**Carl H. Jacobs, PhD**  
Sr. Medical Device Industry Consultant

**Michael Siroky, MD**  
Prof. of Urology, BU School of Medicine

**William Van Buskirk, MD**  
Prof. of Biomedical Engineering, NJIT

**Rafael S. Wurzel, MD**  
Chief, Urology, New Britain Gen'l Hosp.

**Subbarao V. Yalla, MD**  
Prof., Urologic Surgery, Harvard Medical School

## Board of Directors

**Sergio Rothstein, PhD (Chairman)**  
Chairman and CEO, Marsid Realty Co.

**Michael Ehrlich, PhD**  
Ass't. Prof., Finance, NJIT

**Bruce A. Kirchhoff, PhD**  
Prof., Technology Entrepreneurship, NJIT

**Martin Coyne II**  
Founder and Chairman  
CEO Learning Network, LLC

## .....FREEDOM.....FUNCTION.....CONTROL.....

**No Tubes or Bags**  
Simple, Elegant Solution

*Present urinary catheters limit activities, impose dependence on others, and damage the self-image of a patient. Surinate® is self-contained inside the body.*

**Normal Filling/Emptying**  
Restores Quality of Life

*Because it is designed to stay in a patient for 30 days, Surinate® is expected to save patients a great deal of time now lost to daily catheterization routines.*

**On Command Only**  
Total Self-Control

*Patients are likely to require less assistance with Surinate®, with more privacy and thus more incentive to engage in work and social activities.*